Intervention Review

You have full text access to this OnlineOpen article

Progestogens or progestogen-releasing intrauterine systems for uterine fibroids

  1. Ussanee S Sangkomkamhang1,*,
  2. Pisake Lumbiganon2,
  3. Malinee Laopaiboon3,
  4. Ben Willem J Mol4

Editorial Group: Cochrane Menstrual Disorders and Subfertility Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 17 AUG 2012

DOI: 10.1002/14651858.CD008994.pub2

How to Cite

Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BWJ. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD008994. DOI: 10.1002/14651858.CD008994.pub2.

Author Information

  1. 1

    Khon Kaen Hospital, Department of Obstetrics and Gynaecology, Khon Kaen, Thailand

  2. 2

    Khon Kaen University, Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen, Thailand

  3. 3

    Khon Kaen University, Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen, Thailand

  4. 4

    Academic Medical Centre, University of Amsterdam, Obstetrics and Gynaecology, Amsterdam, Netherlands

*Ussanee S Sangkomkamhang, Department of Obstetrics and Gynaecology, Khon Kaen Hospital, Srichan Road, Maung, Khon Kaen, 40000, Thailand. swadpanich@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Inki 2002 {published data only}
  • Inki P, Hurskainen R, Palo P, Ekholm E, Grenman S, Kivela A, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound in Obstetrics & Gynecology 2002;20(4):381-5.
Sayed 2011 {published data only}
  • Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. International Journal of Gynaecology and Obstetrics 2011;112(2):126-30.
Verspyck 2000 {published data only}
  • Verspyck E, Marpeau L, Lucas C. Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2000;89:7-13.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Caird 1997 {published data only}
  • Caird LE,  West CP,  Lumsden MA,  Hannan WJ, Gow SM. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Human Reproduction 1997;12(3):436-40.
Carr 1993 {published data only}
  • Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA,  Byrd W,  et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. Journal of Clinical Endocrinology and Metabolism 1993;76(5):1217-23.
Chan 2007 {published data only}
  • Chan SS,  Tam WH, Yeo W,  Yu MM,  Ng DP,  Wong AW,  et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. International Journal of Gynaecology and Obstetrics 2007;114(12):1510-5.
Chwalisz 2005 {published data only}
  • Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews 2005;26(3):423-38.
Chwalisz 2007 {published data only}
  • Chwalisz K, Larsen L,  Mattia-Goldberg C,  Edmonds A,  Elger W,  Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility 2007;87(6):1399-412.
Friedman 1988 {published data only}
  • Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertility and Sterility 1988;49(3):404-9.
Koh 2007 {published data only}
Levens 2008 {published data only}
  • Levens ED,  Potlog-Nahari C,  Armstrong AY,  Wesley R,  Premkumar A,  Blithe DL, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology 2008;111(5):1129-36.
Magalhaes 2010 {published data only}
  • Magalhaes J, Magalhaes LB. European Journal of Contraception and Reproductive Health Care. The Hague Netherlands, 2010.
Palomba 2002 {published data only}
  • Palomba S,  Sena T,  Morelli M,  Noia R,  Zullo F,  Mastrantonio P. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2002;102(2):199-201.
Rodriguez 2010 {published and unpublished data}
  • Rodriguez MI, Warden M, Darney PD. Intrauterine progestins, progesterone antagonists, and receptor modulators: a review of gynecologic applications. American Journal of Obstetrics and Gynecology 2010;May;202(5):420-8.
Scialli 1995 {published data only}
  • Scialli AR,  Jestila KJ. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertility and Sterility 1995;64(2):313-20.
Siddiqui 2008 {published and unpublished data}
  • Siddiqui M, Hossain F, Banu L. Levonorgestrel intrauterine system Mirena: An update. Bangladesh Journal of Obstetrics and Gynecology 2008;23(1):25-31.
Soysal 2005 {published data only}
  • Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecologic and Obstetric Investigation 2005;59(1):29-35.
West 1992 {published data only}
  • West CP,  Lumsden MA,  Hillier H,  Sweeting V,  Baird DT. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Human Reproduction 1992;7(3):328-32.
Wilkens 2008 {published data only}
  • Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism 2008;Dec;93(12):4664-71.
Yoshida 2010 {published and unpublished data}
  • Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Seminars in Reproductive Medicine 2010;May;28(3):260-73.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Andersen 1993
  • Andersen J, Grine E, Eng CLY, et al. Expression of connexin-43 in human myometrium and leiomyoma. American Journal of Obstetrics and Gynecology 1993;169:1266-76.
Andersen 1998
Borgfeldt 2000
  • Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyomas in a random sample of women aged 25-40 years. Acta Obstetricia et Gynecologica Scandinavica 2000;79:202-7.
Cramer 1990
  • Cramer SAP. The frequency of uterine leiomyomas. American Journal of Clinical Pathology 1990;90:453-8.
David 2005
  • DavidM, Ebert AD. Treatment of uterine fibroids by embolization--advantages, disadvantages, and pitfalls. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2005;123:131–8.
Egger 1997
FIGO 2001
  • FIGO. The International Federation of Gynecology and Obstetrics. Internet 2001.
Flake 2003
  • Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environmental Health Perspectives 2003;111:1037-54.
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JC, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for SystematicReviews of Interventions Version 5.1.0 [updated March2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Kaunitz 2007
Lethaby 2005
Lumbiganon 1996
Manzo 2000
Marsh 2006
Maruo 2004
Maruo 2007
  • Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, Johansson ED. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007;75(6 Suppl):S99-103. Epub 2007 Mar 21.
Okolo 2008
Rein 1995
  • Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. American Journal of Obstetrics and Gynecology 1995 Jan;172(1 Pt 1):14-8.
Silverberg 1986
  • Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. International Journal of Gynecological Pathology 1986;5:235–41.
Singer 1994
  • Singer A, Ikomi A. Successful treatment of fibroids using an intrauterine progesterone device. International Journal of Gynaecology and Obstetrics 1994;46:55.
Starczewski 2000
  • Starczewski A, Iwanicki M. Intrauterine therapy with levonorgestrel-releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekologia Polska 2000;71:1221-5.
Stewart 2001
Stovall 2001
Wallach 2004
WHO 2004
  • Medical eligibility criteria for contraceptive use. WHO. Department of Reproductive Health and Research 2004.
World Contraceptive Use 2005
  • United Nations Population Division. World Contraceptive Use 2005. wall chart. New York, NY: United Nations 2005.
Zapata 2010
  • Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010;82(1):41-55.